# Ipamorelin Research: GH Pulse, IGF-1, and the One Human Trial > Ipamorelin research in depth: the founding selectivity study, human pharmacokinetics, the failed Phase 2 ileus trial, bone-growth and cachexia data, and the GH-axis mechanism. Cited. The GH-axis mechanism, the human pharmacokinetics, the one human efficacy trial, and the rodent findings — read straight and cited to source. ## Before the details Here is the whole ipamorelin research story in one breath. A pharmaceutical lab built it in the 1990s as a cleaner way to make the body release growth hormone (GH) on command. The founding 1998 study proved it could — strongly — while leaving stress hormones alone, which older peptides couldn't manage. A 1999 study measured how fast it moves through the human body. Then it went into one real human trial, for slow bowels after surgery, and that trial failed to beat placebo. Scattered rodent studies since have shown it can grow bone and blunt chemotherapy weight loss in animals. The newest study, from 2024, is in ferrets. That is genuinely it: one elegant mechanism, one negative human efficacy trial, and a thin shelf of animal work. Below, each study gets its own section, with the GH-axis (somatotroph to GH pulse to IGF-1) thread running through all of them. ## The founding study: the first selective GH secretagogue Ipamorelin entered the literature in 1998 as 'the first selective growth hormone secretagogue,' and the title was the finding [1]. In primary rat pituitary cells, anaesthetised rats, and conscious swine, it released GH potently — a swine ED50 of 2.3 nmol/kg, edging out GHRP-6's 3.9 nmol/kg [1]. The decisive result was what it *didn't* do: even at more than 200 times the dose needed for GH release, it left ACTH and cortisol at the level a plain GHRH signal produces [1]. Earlier peptides could not separate the GH signal from the stress-hormone signal; ipamorelin could [1]. That characterization was acute, not chronic — a snapshot of a single, clean pulse, which is the foundation the whole GH-axis story is built on. ## Human pharmacokinetics: a 2-hour half-life and a single 40-minute pulse The one human pharmacokinetic study gave eight healthy men single intravenous infusions across five dose levels (4.21 to 140.45 nmol/kg over 15 minutes) and modeled the result [2]. The kinetics were clean and dose-proportional: a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg [2]. Critically for the GH-axis picture, the GH response was a single discrete pulse peaking around 0.67 hours — about 40 minutes — after dosing [2]. This is one of the only human ipamorelin datasets in existence, and it describes a pulse, not a plateau [2]. ## The one human efficacy trial — and why it matters that it failed The defining human anchor for ipamorelin is a single Phase 2 randomized controlled trial (NCT00672074) [3]. It enrolled 114 adults undergoing open or laparoscopic bowel resection and gave 0.03 mg/kg intravenously twice daily for up to 7 days, testing whether ipamorelin sped recovery of gut function after surgery [3]. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach significance (p=0.15) [3]. On safety, treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific red flag in that short window, but no efficacy either [3]. This is the single most important fact on the site: the only controlled human efficacy test of ipamorelin came back negative [3]. ## Is ipamorelin FDA approved? No. Ipamorelin has never been approved as a drug by the FDA — or any regulator — for any indication [3]. It was investigated, most notably for postoperative ileus in the trial above, but that program ended after the Phase 2 miss and no Phase 3 followed [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, tightening compounding-pharmacy access [3]. It is sold only as a research chemical, and growth hormone secretagogues like it are also banned in sport at all times under the WADA category S2 list [3]. ## Rodent efficacy: bone growth without a measurable IGF-1 bump One of the cleaner rodent findings concerns the skeleton — and it complicates the simple GH-to-IGF-1 story. Subcutaneous ipamorelin at 18, 90, and 450 micrograms per day (split three times daily for 15 days) dose-dependently raised the longitudinal bone growth rate of adult female rats from 42 micrometers per day on vehicle to 44, 50, and 52 micrometers per day [4]. The twist: there was no measurable change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. That points to a partly local, GH-pulse-driven skeletal effect rather than a purely IGF-1-mediated one — a reminder that 'ipamorelin in, IGF-1 up' is not the universal rule the marketing implies [4]. ## The newest data: a 2024 ferret cachexia study The most recent published in-vivo ipamorelin work is a 2024 ferret study [5]. Intraperitoneal ipamorelin at 1 to 3 mg/kg inhibited cisplatin-induced body-weight loss by roughly 24% on the last day of the delayed phase (48 to 72 hours), but had no anti-emetic effect on either acute or delayed chemotherapy-induced vomiting — unlike a related compound, anamorelin, which cut acute emesis by 60% when given into the brain [5]. The takeaway is narrow and honest: ipamorelin blunted chemotherapy-associated weight loss through a peripheral mechanism, but it is not an anti-nausea agent [5]. ## Does it survive chronic dosing and glucocorticoids? Two rat studies address durability. In young female rats, 21 days of ipamorelin increased the volume of secretory granules in pituitary GH-making cells, and their cells still responded strongly to a fresh ipamorelin challenge afterward — arguing against rapid tolerance (tachyphylaxis) under that protocol [7]. Separately, eight days of the steroid methylprednisolone did not blunt the acute GH response to ipamorelin in rats, and the combination actually raised IGF-1 and improved body-weight recovery versus steroid alone [8]. Both findings reinforce that ipamorelin's GH-release machinery is fairly robust — it keeps working under repeated dosing and under glucocorticoid load, at least in rodents [7][8]. ## Ipamorelin cjc-1295 The most popular research pairing is ipamorelin with CJC-1295, and the rationale is mechanistic, not trial-proven. CJC-1295 is a long-acting GHRH analog — it works on a *different* receptor (the GHRH receptor) than ipamorelin's ghrelin receptor, so the two push the GH axis through complementary doors [10]. In healthy adults, a single subcutaneous CJC-1295 dose produced dose-dependent 2- to 10-fold GH increases for 6+ days and 1.5- to 3-fold sustained IGF-1 elevation, while preserving the natural pulsing rhythm of GH [10]. Pulsatile GH secretion persisted even under continuous GHRH-analog stimulation, which is the physiology often invoked to justify combining a steady GHRH analog with a pulsing GHRP like ipamorelin [11]. Important caveat: those CJC-1295 numbers are from CJC-1295 studies, and the *combination* has never been tested in a trial for any outcome — the stack rests on two single-agent stories, not a combination study [10][3]. ## Ipamorelin vs sermorelin Ipamorelin and sermorelin are often compared, but they are different tools that hit different receptors. Ipamorelin is a GHRP — it activates the ghrelin receptor (GHS-R1a) to fire a GH pulse [1]. Sermorelin is a GHRH analog — it mimics growth-hormone-releasing hormone and works on the GHRH receptor instead [10]. Because they act through complementary pathways, the two are conceptually closer to teammates than rivals: one (ipamorelin) supplies the pulsing ghrelin-side signal, the other (a GHRH analog) supplies the steady GHRH-side signal, and the same complementary logic underlies the CJC-1295 pairing above [10][11]. On evidence, neither has a positive human efficacy trial for anti-aging or body composition; ipamorelin's one human efficacy trial was negative [3]. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin is a comparison across two different drug classes. Tesamorelin, like sermorelin and CJC-1295, is a GHRH analog acting on the GHRH receptor — not a ghrelin-receptor peptide like ipamorelin [10]. The mechanistic difference is the same one that runs through this whole page: ipamorelin pulses the GH axis from the ghrelin-receptor side, while GHRH analogs drive it from the GHRH side [1][10]. The two classes are complementary in mechanism, which is exactly why GHRP-plus-GHRH-analog pairings exist in research protocols [11]. As with every comparison here, ipamorelin itself has no positive human outcome trial — its single Phase 2 efficacy test failed [3]. --- A bright, plain-English reading of the Ipamorelin record — the clean ghrelin-receptor GH pulse traced to IGF-1 and cited to source, the one failed human trial kept in full view beside the rodent data, and the community reports pinned plainly to one side as anecdote; no clinic behind the page, and nothing here dosed, dispensed, or sold.